|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To confirm these data on the protein level, we executed immunohistochemical (IHC) staining against MED15 on a tissue microarray containing 184 samples of the most common subtypes of the tumour at the various stages.
|
29400661 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Genetic alterations of the mediator subunit 15 (MED15) in separate tumor entities have been described previously.
|
30127891 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The tazarotene-induced gene 1 (TIG1) protein is a retinoid-inducible growth regulator and is considered a tumor suppressor.
|
29902837 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, analyzing data from The Cancer Genome Atlas-Liver Hepatocellular Carcinoma (TCGA-LIHC) and GSE14520 datasets revealed a significant correlation between MED15 expression and the tumor size (P=0.033), Barcelona Clinic Liver Cancer stage (P=0.031), α-fetoprotein levels (P=0.002) and metastasis risk (P=0.001).
|
29556287 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Retinoic Acid Receptor Responder (RARRES1)/ Tazarotene-induced gene-1 (TIG-1) is a putative tumor suppressor gene that exerts its tumor suppressor function via unknown mechanisms.
|
28678839 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The expression of TIG1 is decreased in malignant prostate carcinoma or poorly differentiated colorectal adenocarcinoma, but TIG1 is present in benign or well-differentiated tumors.
|
27989102 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
MED15 overexpression in primary tumors from patients who developed recurrences was associated with higher mortality rates and occurred at highest frequency in oral cavity or oropharyngeal tumors.
|
25791637 |
2015 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
More importantly, TIG1 methylation status was related to tumor size (P = 0.015), histological differentiation (P = 0.004), and tumor stage (P < 0.001).
|
24006221 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The tazarotene-induced gene 1 (TIG1) is a putative tumor suppressor gene.
|
22126303 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tazarotene-induced gene 1 (TIG1) is a retinoid-inducible type II tumour suppressor gene.
|
21575264 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We investigated expression and mutation status of TIG1 in primary gastric tumors and cell lines to explore the candidacy of the gene as a tumor suppressor.
|
19806788 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, the methylated TIG1 sequence was detected in 39 of 43 (90.7%) primary NPC tumors by MSP.
|
15455391 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our data suggest that C/ebpalpha and Tig1 function as tumor suppressor proteins in endometrial cancers and that their reexpression may be a therapeutic target.
|
15886297 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Hypermethylation of CpG islands has been associated with silencing of various tumor suppressor genes, and the retinoid acid receptor beta (RARbeta), cellular retinol-binding protein 1 (CRBP1), and tazarotene-induced gene 1 (TIG1) genes have been associated with retinoic acid signaling.
|
16134180 |
2005 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
There was no correlation between TIG1 promoter methylation and that of retinoid acid receptor beta2 (RARbeta2), another retinoic-induced putative tumor suppressor gene (P = 0.78).
|
15059893 |
2004 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
TIG1 expression in normal tissues and cell lines was analyzed by northern blot and in normal and tumor prostate tissue sections by in situ hybridization.
|
11929948 |
2002 |